

# Supplemental material for Wolock et al. 2023

Timothy M Wolock      Seth Flaxman      Tiwonge Chimpandule  
Stone Mbiriyawanda      Andreas Jahn      Rose Nyirenda      Jeffrey W Eaton

13 January 2023

## Contents

<b>1</b>	<b>Detailed methodology</b>	<b>1</b>
1.1	Data sources . . . . .	1
1.2	Model overview . . . . .	2
1.3	Compartmental model of HIV . . . . .	2
1.4	Observation model . . . . .	10
1.5	Model selection methods . . . . .	14
<b>2</b>	<b>Model selection results</b>	<b>15</b>
<b>3</b>	<b>Fit in all districts</b>	<b>18</b>
<b>4</b>	<b>Comparison to UNAIDS 2021 estimates (UNAIDS 2021)</b>	<b>46</b>
	<b>References</b>	<b>47</b>

## 1 Detailed methodology

This section describes the general model framework and definitions of data sources, without reference to country-specific implementation. Details about specific data sources and inputs for Malawi are described in the main text.

### 1.1 Data sources

The collated set of data,  $\mathcal{D}$ , considered by our model consists of a subset of household surveys, ANC facility HIV test results, and ART programme patient counts. Table 1 outlines the data sources and the indicators they measure. Table 2 outlines the exact data sources used in this analysis.

Supplemental Table 1: Taxonomy of population-level HIV data sources included in our model

Indicator	Data Source	Numerator	Denominator
Prevalence	Household surveys	# of positive HIV tests	# of HIV tests
ANC prevalence	Sentinel ANC clinics and routine ANC testing	# of positive HIV tests	# of HIV tests
ART coverage	Household surveys	# of positive ART tests	# of ART tests
ART patients	Routine health service delivery data	# of ART patients	-
Recency status	Household surveys	# of positive recency assays	# of recency assays

Supplemental Table 2: Population-level data sources from Malawi used in this analysis.

Name	Type	Years	Prevalence	Treatment	Recency
2004 DHS	HH Survey	2004	✓		
2010 DHS	HH Survey	2010	✓		
2015-2016 DHS	HH Survey	2015-2016	✓		
MPHIA 2015-2016	HH Survey	2015-2016	✓	✓	✓
UNAIDS ANC Data	Sentinel surveillance	1995-2010	✓		
DHAMIS	Facility reports	2011-present	✓		
DHAMIS	Facility reports	2005-present		✓	

## 1.2 Model overview


The model represents the dynamics necessary to simulate an epidemic model as non-linear functions of time, space, and sex (Hastie and Tibshirani 1986), aggregates the epidemic model's projections to produce estimates, and uses the observation model to relate those estimates to data. For a single draw from the posterior density:

1. A set of process parameters,  $\theta_P$ , are used to model region-/sex-/time-specific series of HIV transmission rates, ART initiation rates, and initial prevalence.
2. The epidemic model is initialised at the state determined by the estimated initial prevalence from (1) and integrated using the estimated transmission rates, ART initiation rates, and a set of exogenous, fixed parameters.
3. Predictions from the epidemic model are aggregated to produce estimates of HIV prevalence, ART coverage, and ART patients at the same spatio-temporal resolution as each dataset.
4. Predicted HIV prevalence, incidence, and ART coverage are used with an additional set of parameters,  $\theta_O$ , to evaluate the observation model given a collated dataset  $\mathcal{D}$ .

Figure 1 presents a simplified representation of the model. The first step from the above list is represented by every node to the left of  $M$ , the second step is  $M$ , and the third step is to the right of  $M$ .

## 1.3 Compartmental model of HIV

We use a deterministic compartmental model of HIV to simulate HIV prevalence and incidence, ART coverage, and the number of PLHIV receiving treatment ( $\rho_{r,g}(t)$ ,  $\lambda_{r,g}(t)$ ,  $\alpha_{r,g}(t)$ , and  $A_{r,g}(t)$ , respectively).




Supplemental Figure 1: A simplified graphical representation of our model of HIV incidence. Diamonds are parameters, white circles are (deterministic) calculations, and blue squares are external data. Red parameters influence the process model, and green/yellow parameters influence the observation model.

43 We model the number of people of sex  $g$  in region  $r$  at time  $t$  by disease status with the following set of  
 44 ordinary differential equations:

$$\begin{aligned}
 \frac{\partial S_{r,g}(t)}{\partial t} &= S_{r,g}(t) \cdot (-\lambda_{r,g}(t) - \mu_{t,g}^S) + E_{r,t,g}^S \\
 \frac{\partial I_{r,g,c}(t)}{\partial t} &= I_{r,g,c}(t) \cdot (-\mu_{t,g}^S + \mu_{t,g,c}^I - \alpha_{r,t,g,c}^* - \iota_{g,c,t}) + \lambda_{r,g,c}(t)S_{r,g}(t) + \\
 &\quad \eta A_{r,g,c}(t) + \iota_{g,c-1}I_{r,g,c-1}(t) + E_{r,t,g,c}^I \\
 \frac{\partial A_{r,g,c}(t)}{\partial t} &= A_{r,g,c}(t) \cdot (-\mu_{t,g}^S - \mu_{t,g,c}^A - \eta) + \alpha_{r,t,g,c}^*I(t) + E_{r,t,g,c}^A.
 \end{aligned} \tag{1}$$

45 This model is solved using the forward Euler method with a step size of 0.25 years. We denote the  
 46 number of susceptibles  $S_{r,g}(t)$ , the number infected in disease stage  $c$  without treatment  $I_{r,g,c}(t)$ , and the  
 47 number infected with treatment who began treatment at disease stage  $c$   $A_{r,g,c}(t)$ . We define  $c$  to be one of  
 48 four CD4 compartments, consistent with those defined by the Thembisa model (Johnson and Dorrington  
 49 2019). Figure 2 outlines the structure of disease progression in the model.

50 A susceptible individual can either die at rate  $\mu_{t,g}^S$  or become infected through contact with the opposite  
 51 sex at rate  $\lambda_{r,g}(t)$ . An infected individual without treatment can die at rate  $\mu_{t,g}^S + \mu_{t,g,c}^I$ , begin treatment  
 52 with probability  $\alpha_{r,t,g,c}^*$  or progress to the next disease stage at rate  $\iota_{g,c,t}$ . Finally, an individual on  
 53 treatment can die at rate  $\mu_{t,g}^S + \mu_{t,g,c}^A$  or interrupt treatment with annual probability  $\eta$ . Treatment  
 54 interruption is difficult to measure, so we have fixed  $\eta$  to be 6% annually, adjusting a published figure to  
 55 account for improvements in the treatment programme (Yu et al. 2007).



Supplemental Figure 2: Diagram of compartmental model of HIV used in this analysis

56 We stratify PLHIV with and without treatment into four CD4 categories to accurately model the survival  
 57 distribution from HIV infection to AIDS-related death and to be able to capture changing eligibility for  
 58 ART in which treatment was restricted to those with the lowest CD4 counts.

59 We calculate the CD4 stage progression rates,  $\iota_{g,c,t}$ , using assumptions described by Johnson and  
 60 Dorrington (2019). Taking the average time spent in each CD4 category from Table 3.1, we apply Equation  
 61 3.1 to the Spectrum-estimated year-/sex-specific average age of PLHIV between 15-49:

$$\iota_{g,c,t} = \iota_c 0.96^g (1+k)^{(x-30)/10}, \quad (2)$$

62 where  $\iota_c$  is the average annual rate of progression from category  $c$  to  $c+1$ , 0.96 is the progression rate  
 63 of women relative to men, and  $k = 0.18$  is the proportionate increase in progression associated with a  
 64 ten-year increase age. Following Table 3.1, we fix  $\iota = (3.16, 2.13, 3.20)$  to be the expected number of years  
 65 spent in CD4 category without treatment for the three highest CD4 categories. The final category is  
 66 terminal, so its expected duration is not defined. The age distribution of PLHIV from Spectrum is itself  
 67 an estimate and therefore might be inaccurate or contain uncertainty, which is not considered here; the  
 68 approach described above is a simple solution to account for limitation that the model does not explicitly  
 69 represent age structure.

70 To account for the shifting age distribution of PLHIV and gradual improvement of HIV patient outcomes  
 71 without treatment in SSA, we calculate age-adjusted mortality rates based on the assumptions and results  
 72 from EPP-ASM (Eaton et al. 2019). We use input mortality rates and predicted counts of PLHIV by age in  
 73 each CD4 bin to find year-/age-/sex-/CD4-specific expected death counts. We aggregate the death and  
 74 population counts to align them with the year-/sex-/CD4 groups used here and recalculate the mortality  
 75 rates.

76 Each  $E$  term in Equation (1) is the net number of people ageing in or out of the 15-49 year old population.  
 77 HIV prevalence varies systematically with age in sub-Saharan Africa, so we must consider the possibility  
 78 that the distributions of people ageing in and out across compartment vary from those of the general  
 79 population. For example, if the population of PLHIV is ageing, we would expect prevalence among  
 80 people ageing out to increase over time.

81 We use population data and national age-/sex-specific estimates of the share of people in each disease  
 82 compartment from Spectrum to obtain regional estimates of the number of people turning 15 and 50  
 83 years old by sex,  $E_{r,t,g}^{15}$  and  $E_{r,t,g}^{50}$ , respectively. The national-level estimates from Spectrum inherently  
 84 weigh each region proportionately to its population, so if the regional distribution of individuals across  
 85 compartment is correlated with population, the national-level disease status distributions will represent  
 86 smaller regions poorly. We therefore apply region-specific adjustments to the estimated Spectrum  
 87 distributions at each time point. Specifically, we adjust the odds from Spectrum of being in stage  $c$  of  
 88 compartment  $C$  relative to being susceptible with the model's current regional prediction. Taking people  
 89 ageing in as an example, the adjusted odds of an individual being in CD4 bin  $c$  relative to not being  
 90 infected with HIV are:

$$\Delta_{t,g,c}^{15,C} = \frac{C_{r,g,c}(t) C_{g,c,t}^{15,Spec}}{S_{r,g}(t) S_{g,t}^{15,Spec}} \quad (3)$$

91 noting that the denominators have cancelled. Then, fixing  $o_{t,g}^{15,S} = 1.0$ , we solve for the proportion of  
 92 people in each compartment:

$$v_{t,g,c}^{15,C} = \frac{\Delta_{t,g,c}^{15,C}}{1 + \sum_{J \in I,A} \sum_{i=1}^4 \Delta_{t,g,i}^{15,J}} \quad (4)$$

93 Finally, we calculate the net numbers of people ageing in and out for a given compartment,  $C$  as

$$E_{r,t,g,c}^C = v_{t,g,c}^{15,C} E_{r,t,g}^{15} - v_{t,g,c}^{50,C} E_{r,t,g}^{50}. \quad (5)$$

94 This method accounts for the possibility that the distributions of people ageing into or out of the  
 95 population across compartment vary from that of the general population.

96 We calculate prevalence as

$$\rho_{r,g}(t) = \frac{\sum_{c=1}^4 [I_{r,g,c}(t) + A_{r,g,c}(t)]}{S_{r,g}(t) + \sum_{c=1}^4 [I_{r,g,c}(t) + A_{r,g,c}(t)]} \quad (6)$$

97 and ART coverage as

$$\alpha_{r,g}(t) = \frac{\sum_{c=1}^4 A_{r,g,c}(t)}{\sum_{c=1}^4 [I_{r,g,c}(t) + A_{r,g,c}(t)]}. \quad (7)$$

98 With the compartmental model defined, we will define the models for incidence, ART initiation, and  
 99 the initial state of the model, denoted  $\lambda_{r,g}(t)$ ,  $\alpha_{r,t,g,c}^*$  and  $(S_{r,g}(0), I_{r,g}(0), A_{r,g}(0))$ , respectively, for all  
 100  $r \in \{1, \dots, R\}$  and  $g \in \{0, 1\}$ .

### 101 1.3.1 Generalised additive models for HIV transmission and ART initiation rates

102 We assume that a subset of the dynamics governing the compartmental model (mortality, disease  
 103 progression, etc.) are fixed and drawn from other data sources and models, but three key components  
 104 (incidence, ART initiation rate, and the initial state) are inferred from data. Each of these quantities is  
 105 represented by an underlying generalised additive model (Hastie and Tibshirani 1986).

106 **1.3.1.1 Model of HIV incidence** We model incidence,  $\lambda_{r,g}(t)$ , as a log-linear function of time-varying  
 107 transmission rates, opposite-sex prevalence, and ART coverage. Specifically, we have:

$$\begin{aligned} \log \lambda_{r,g,c}(t) = & \log \xi_c + g \cdot (\psi + vt) + \log \kappa_{r,t} + \\ & (I_{r,g^*,c}(t) + (1 - \omega)A_{r,g^*,c}(t))/N_{g,r}. \end{aligned} \quad (8)$$

108 We use the relative infectiousness ratios listed in Table 3.1 in Johnson and Dorrington (2019) to fix the  
 109 values of  $\xi_c$  and set the following priors on the sex ratio of transmission parameters:

$$\psi, v \sim N(0, 5). \quad (9)$$

110 In Wolock (2022), an alternative specification for this model that allowed for transmission across districts  
 111 was considered. There was little empirical difference between models that included cross-district spatial  
 112 transmission dynamics and those that did not. The model specification study performed in Chapter 4 of  
 113 that thesis indicated slightly that the model without spatial transmission offered the best out-of-sample  
 114 fit out of a set of candidate models.

115 Mathematically, the incidence rate,  $\lambda_{r,g}(t)$ , is only constrained to be greater than zero, but numerical  
 116 simulation of the system of ODEs in Equation (1) is not well constrained and negative predictions can  
 117 disrupt the inference procedure. Therefore, we calculate the HIV infection probability during a single  
 118 time step of duration  $h$  attributable to all disease stages combined by aggregating the stage-specific rates  
 119 and finding the probability of infection:

$$\lambda_{r,g}(t) = 1 - \exp \left[ -h \sum_{c=1}^4 \lambda_{r,g,c}(t) \right]. \quad (10)$$

120 We use this transformation to avoid numerical problems during the inference procedure; all reported

121 region-level incidence here are per person-year.

122 **1.3.1.1.1 Spatio-temporal HIV transmission rates** The model allows the transmission rate of HIV to  
 123 vary by time, region, sex, and transmitting CD4 category. The relative infectiousness by transmitting  
 124 CD4 category is based on fixed assumptions, and the other dynamics are inferred. We model the  
 125 log-transformed region-/time-specific HIV transmission rate,  $\log \kappa_{r,t}$ , with a hierarchical linear model:

$$\begin{aligned}
 \log \kappa_{r,t} &= \kappa_0 + \kappa_r + (\gamma_0^\kappa + \gamma_r^\kappa) \cdot t + \sum_{i=1}^{K_\kappa+1} \beta_{i,r}^\kappa \phi_i^\kappa(t) \\
 \kappa_0 &\sim N(0, 5) \\
 \kappa_r &\sim N(0, \sigma_\kappa) \\
 \gamma_0^\kappa &\sim N(0, 5) \\
 \gamma_r^\kappa &\sim N(0, \sigma_{\gamma^\kappa}) \\
 \beta_{i,r}^\kappa &\sim \text{ARIMA}_{\sigma_{\beta^\kappa}, \theta_{\beta^\kappa}}(1, d, 0) \\
 \sigma_\kappa, \sigma_{\gamma^\kappa}, \sigma_{\beta^\kappa} &\sim N^+(0, 1) \\
 \text{logit } \theta_{\beta^\kappa} &\sim N(0, \sqrt{1/0.15}) \\
 \beta_{1,r}^\kappa &= 0.
 \end{aligned} \tag{11}$$

126 where  $\kappa_0$  is a shared intercept,  $\kappa_r$  is a regional intercept and  $\gamma_0^\kappa$  and  $\gamma_r^\kappa$  are mean and region-specific  
 127 slopes with respect to time. The remainder of the model for  $\kappa_{r,t}$  defines a spline model with coefficients  
 128 distributed according to an autoregressive integrated moving average (ARIMA) model (Hyndman and  
 129 Athanasopoulos 2018). In this model,  $K_\kappa$  is the number of knots,  $\beta_{i,r}^\kappa$  is a region-specific coefficient for  
 130 basis function  $i$  and  $\phi_i^\kappa$  is the  $i$ 'th basis function.

131 Returning to Equation (11), we specify that only one autoregressive term and no moving average terms  
 132 may be included but do not specify the order of difference. All else equal, higher order differencing  
 133 should result in a smoother curve. We assessed the choice of  $d$  in the model comparison study (Section  
 134 1.5).

135 The model of incidence contributes the following parameters to  $\theta_P$ : a transmission rate sex log-ratio,  $\psi$ , a  
 136 transmission rate intercept,  $\kappa_0$ , a set of regional intercepts,  $\kappa_r$ , a mean transmission rate slope with respect  
 137 to time,  $\beta_0^\kappa$ , a set of regional slopes,  $\beta_r^\kappa$ , and two standard deviations,  $\sigma_r^\kappa$  and  $\sigma_{\beta^\kappa}$ , which are outlined in  
 138 Table 3.

139 **1.3.1.2 Model of ART initiation** We use a similar log-linear regression approach to model region-  
 140 /time-/sex-/substage-specific ART initiation rates (an outcome similarly not observed directly):

Supplemental Table 3: Parameters used in the model of HIV transmission rates. Indexed parameters are estimated for all possible values of that index.

Param	Size	Description	Prior
$\psi$	1	Log-incidence rate sex ratio	$N(0, 5)$
$v$	1	Log-incidence rate sex ratio slope	$N(0, 5)$
$\kappa_0$	1	Log-transmission rate mean intercept	$N(0, 5)$
$\kappa_r$	$R$	Log-transmission rate region intercept	$N(0, \sigma_\kappa)$
$\sigma_\kappa$	1	Log-transmission rate region intercept SD	$N^+(0, 1)$
$\gamma_0^\kappa$	1	Log-transmission rate mean slope	$N(0, 5)$
$\gamma_r^\kappa$	$R$	Log-transmission rate mean regional slope	$N(0, \sigma_{\beta^\kappa})$
$\sigma_{\gamma^\kappa}$	1	Log-transmission rate region slope SD	$N^+(0, 1)$
$\beta_{i,r}^\kappa$	$R \times K_\kappa + 1$	Log-transmission rate regional spline coefficient	$\text{ARIMA}_{\sigma_{\beta^\kappa}, \theta_{\beta^\kappa}}(1, d, 0)$
$\sigma_{\beta^\kappa}$	1	Log-transmission rate region ARIMA SD	$N^+(0, 1)$
$\text{logit } \theta_{\beta^\kappa}$	1	Log-transmission rate region ARIMA autocorrelation SD	$N^+(0, \sqrt{1/0.15})$

$$\begin{aligned}
\log \alpha_{r,t,g,c}^* &= \zeta_{c,g} + g \cdot \chi + \alpha_0^* + \alpha_r^* + (\gamma_0^{\alpha^*} + \gamma_r^{\alpha^*}) \cdot t + \sum_{i=1}^{K_\alpha+1} \beta_{i,r}^{\alpha^*} \phi_i^{\alpha^*}(t) \\
\alpha_0^* &\sim N(0, 5) \\
\alpha_r^* &\sim N(0, \sigma_{\alpha^*}) \\
\gamma_0^{\alpha^*} &\sim N(0, 5) \\
\gamma_r^{\alpha^*} &\sim N(0, \sigma_{\gamma^{\alpha^*}}) \\
\beta_{i,r}^{\alpha^*} &\sim \text{ARIMA}_{\sigma_{\beta^{\alpha^*}}, \theta_{\beta^{\alpha^*}}}(1, 2, 0) \\
\sigma_{\alpha^*}, \sigma_{\gamma^{\alpha^*}}, \sigma_{\beta^{\alpha^*}} &\sim N^+(0, 1) \\
\text{logit } \theta_{\beta^{\alpha^*}} &\sim N(0, \sqrt{1/0.15}) \\
\beta_{1,r}^{\alpha^*} &= 0.
\end{aligned} \tag{12}$$

141 This model has region-specific log-linear models with respect to time with additional region-specific  
142 ARIMA error term. Here,  $\zeta_{c,g}$  is a sex-/stage-specific rate of ART initiation,  $\chi$  is an inferred intercept  
143 among women,  $\alpha_0^*$  is a mean intercept,  $\alpha_r^*$  is a regional intercept,  $K_\alpha$  is a number of knots,  $\beta_{i,r}^{\alpha^*}$  is a regional  
144 spline coefficient,  $\phi_i$  is a spline basis function, and  $\sigma_{\alpha^*}$ ,  $\sigma_{\gamma^{\alpha^*}}$ , and  $\sigma_{\beta^{\alpha^*}}$  are standard deviations. To prevent  
145 the autoregressive model from being rank deficient, we fix the first coefficient in the regional splines to  
146 be zero. In the results we present here, we set  $\phi$  to be an order-two spline with annual knots, effectively  
147 linearly interpolating between inferred annual values.

148 For all  $t$  before ART was scaled up in any given region, we fix  $\phi_i(t)$  to be zero. The baseline ART initiation  
149 rate  $\zeta_{c,g}$  is defined as  $\mu_{c,g}^I / \mu_{1,1}^I$ , the ratio of mortality in CD4 stage  $c$  relative to women in stage 1. This  
150 encodes an assumption that PLHIV at stage  $c$  initiate treatment in proportion to the expected mortality  
151 in  $c$ . This model of ART initiation contributes the following parameters to  $\theta_P$ : an intercept,  $\alpha_0^*$ , a set of  
152 region random effects,  $\alpha_r^*$ , set of spline coefficient means, mean and region-specific slopes,  $\gamma_0^{\alpha^*}$  and  $\gamma_r^{\alpha^*}$ , a  
153 set of regional spline coefficients,  $\beta_{i,r}^{\alpha^*}$ , three standard deviations,  $\sigma_{\alpha^*}$ ,  $\sigma_{\gamma^{\alpha^*}}$ , and  $\sigma_{\beta^{\alpha^*}}$ , and an autoregressive  
154 parameter  $\theta_{\beta^{\alpha^*}}$ , which are outlined in Table 4.



Supplemental Table 4: Parameters used in the model of ART initiation. Indexed parameters are estimated for all possible values of that index.

Param	Size	Description	Prior
$\chi$	1	Log-ART initiation rate sex effect	$N(0, 5)$
$\alpha_0^*$	1	Log-ART initiation rate mean intercept	$N(0, 5)$
$\alpha_r^*$	$R$	Log-ART initiation rate regional intercept	$N(0, \sigma_{\alpha^*})$
$\sigma_{\alpha^*}$	1	Log-ART initiation rate regional intercept SD	$N^+(0, 1)$
$\gamma_0^{\alpha^*}$	1	Log-ART initiation rate mean slope	$N(0, 5)$
$\gamma_r^{\alpha^*}$	$R$	Log-ART initiation rate regional slope	$N(0, \sigma_{\gamma^{\alpha^*}})$
$\sigma_{\gamma^{\alpha^*}}$	1	Log-transmission rate region slope SD	$N^+(0, 1)$
$\beta_{l,r}^{\alpha^*}$	$R \times K_{\alpha} + 1$	Log-ART initiation rate regional spline coefficient	$ARIMA_{\sigma_{\beta^{\alpha^*}}, \theta_{\beta^{\alpha^*}}}(1, 2, 0)$
$\sigma_{\beta^{\alpha^*}}$	1	Log-ART initiation rate region ARIMA SD	$N^+(0, 1)$
$\text{logit } \theta_{\beta^{\alpha^*}}$	1	Log-ART initiation rate region ARIMA autocorrelation SD	$N^+(0, \sqrt{1/0.15})$
$\delta_0$	1	Mean ANC bias	$N(0, 5)$

155 **1.3.1.3 Model of initial state** Region-/sex-specific initial prevalence is modelled with a logit-linear  
 156 model:

$$\begin{aligned}
 \text{logit } \rho_{r,g}(0) &= \rho_r + g \cdot \epsilon \\
 \rho_r &\sim N(\rho_0, \sigma_{\rho}) \\
 \rho_0 &\sim N(0, 5) \\
 \sigma_{\rho} &\sim N^+(0, 1)
 \end{aligned} \tag{13}$$

157 where  $\rho_0$  is cross-region logit-transformed mean prevalence at time 0,  $\rho_r$  is a regional deviation from  $\rho_0$ ,  
 158  $\epsilon$  is an intercept for prevalence among women (recalling that  $g = 1$  among women), and  $\sigma_{\rho}$  is a standard  
 159 deviation for the random effects. We calculate  $\epsilon$  from Spectrum estimates as the log-ratio of female  
 160 prevalence to male prevalence.

161 To maintain consistency with other national-level estimates of prevalence, we put a prior on initial  
 162 prevalence among men:

$$\begin{aligned}
 \hat{\rho}_{\text{Nat}} &\sim N(\rho_{\text{Nat}}, 0.005) \\
 \hat{\rho}_{\text{Nat}} &= \frac{1}{P_{\text{Nat},0}(0)} \sum_{r=1}^R \frac{P_{r,0}(0)}{1 + \exp(-\rho_{r,0})},
 \end{aligned} \tag{14}$$

163 where  $P_{r,0}(0)$  is initial male population in region  $r$  and  $P_{r,0}(0)/(1 + \exp(-\rho_{r,0}))$  is estimated male  
 164 PLHIV in region  $r$ . This prior encourages the model to match external estimates of initial prevalence,  
 165 without sacrificing subnational variation. The inverse logit-transformed mean of the random effects,  
 166  $1/(1 + \exp(-\rho_0))$ , cannot be compared directly to exogenous initial prevalence  $\rho_{\text{Nat}}$ , because  $\rho_{\text{Nat}}$  is  
 167 implicitly population-weighted.

168 We assume that  $t = 0$  is before ART scale-up, so  $A_{r,g,c}(0) = 0$  in all cases. Making fixed assumptions  
 169 about the distribution of PLHIV across disease substage without treatment, we calculate  $I_{r,g,c}(0)$  and  
 170 solve for  $S_{r,g,c}(0)$ :

Supplemental Table 5: Parameters used in the model of the initial state. Indexed parameters are estimated for all possible values of that index.

Param	Size	Description	Prior
$\rho_0$	1	Initial mean prevalence	$N(0, 5)$
$\rho_r$	$R$	Initial regional prevalence	$N(0, \sigma_\rho)$
$\sigma_\rho$	1	Initial prevalence SD	$N^+(0, 1)$

$$\begin{aligned}
 I_{r,g,c}(0) &= b_{g,c} \cdot \rho_{r,g}(0) \cdot P_{r,g}(0) \\
 S_{r,g}(0) &= P_{r,g}(0) - \sum_{c=1}^4 (I_{r,g,c}(0)) \\
 A_{r,g,c}(0) &= 0.
 \end{aligned} \tag{15}$$

171 where  $b_{g,c}$  is the share of PLHIV of sex  $g$  in CD4 stage  $c$  at time zero derived from Spectrum model  
 172 estimates.  $P_{r,g}(0)$  is the population at time zero for sex  $g$  in region  $r$ , which is assumed to be a fixed  
 173 known input.

174 This model adds the following parameters to  $\theta_P$ : a national mean,  $\rho_0$ , regional deviations from the  
 175 means,  $\rho_r$ , and one standard deviation,  $\sigma_\rho$ , which are outlined in Table 5.

## 176 1.4 Observation model

### 177 1.4.1 Household surveys

178 We assume that national household surveys are probability random samples within each region, so if  $s$  is  
 179 a household survey,  $Y_{r,t,g}^{s,\text{HIV}} / T_{r,t,g}^{s,\text{HIV}}$ , provides an unbiased estimate of true prevalence in demographic  
 180 segment  $\{r, t, g\}$  where  $Y$  and  $T$  are the design-weighted effective count and effective sample size,  
 181 respectively. We therefore assume that  $Y_{r,t,g}^{s,\text{HIV}}$  is a sample from a binomial distribution with  $T_{r,t,g}^{s,\text{HIV}}$  trials  
 182 each with a probability of  $\rho_{r,g}(t)$ :

$$Y_{r,t,g}^{s,\text{HIV}} \sim \text{Binom}(T_{r,t,g}^{s,\text{HIV}}, \rho_{r,g}(t)). \tag{16}$$

183 Defining a binomial distribution using the effective count and effective sample size is a computationally  
 184 efficient way to approximate the effect of the complex multi-stage survey design (Chen, Wakefield,  
 185 and Lumley 2014) and is increasingly common in recent HIV mapping exercises (Eaton et al. 2021;  
 186 Dwyer-Lindgren et al. 2019).

187 We make a similar assumption about survey-estimated ART coverage:

$$Y_{r,t,g}^{s,\text{ART}} \sim \text{Binom}(T_{r,t,g}^{s,\text{ART}}, \alpha_{r,g}(t)). \tag{17}$$

188 HIV recent infection assays (or “recency assays”) indicate whether an individual was infected in the  
 189 recent past, so estimated incidence and prevalence must be combined to estimate the proportions that

190 are recent. We use the estimator from Kassanjee, McWalter, and Welte (2014) as modified by Eaton et al.  
 191 (2021) to find this proportion:

$$v_{r,g}(t) = \frac{\lambda_{r,g}(t) \cdot (1 - \rho_{r,g}(t)) \cdot (\Omega_R - \gamma_R) + \gamma_R \rho_{r,g}(t)}{\rho_{r,g}(t)}, \quad (18)$$

192 where  $\Omega_R$  is the mean duration of recent infection (fixed at 130/365), and  $\gamma_R$  is the proportion of positive  
 193 recency assays that are false positives (fixed at 0). As before, we assume that each  $Y_{r,t,g}^{s,Rec}$  is a sample from  
 194 a binomial distribution:

$$Y_{r,t,g}^{s,Rec} \sim \text{Binom}(T_{r,t,g}^{s,Rec}, v_{r,g}(t)). \quad (19)$$

195 Because the mean duration of recent infection and recency assay false positive rate are fixed, the  
 196 observation models for survey data do not contribute any parameters to the model.

#### 197 1.4.2 ANC facility data

198 HIV prevalence among ANC attendees is not representative of HIV prevalence among the general  
 199 population, so we cannot estimate  $\rho_{r,1}(t)$  with  $Y_{r,t,1}^{s,HIV} / T_{r,t,1}^{s,HIV}$ . Instead, following Bao (2012), we estimate  
 200 site-specific ANC prevalence as a function of general population prevalence and facility effects

$$\begin{aligned} \text{logit } \rho_{r,1}^s(t) &= \text{logit } \rho_{r,1}(t) + \delta_0 + \delta_s + (\epsilon_0 + \epsilon_s) \cdot t \\ \delta_0, \epsilon_0 &\sim \text{N}(0, 5) \\ \delta_s &\sim \text{N}(0, \sigma_\delta) \\ \epsilon_s &\sim \text{N}(0, \sigma_\epsilon) \\ \sigma_\delta, \sigma_\epsilon &\sim \text{N}(0, 1), \end{aligned} \quad (20)$$

201 where  $\delta_s$  is a facility-specific random effect,  $\delta_0$  is a mean ANC offset,  $\epsilon_0$  is a mean slope with respect to  
 202 time,  $\epsilon_s$  is a site-specific slope, and  $\sigma_\delta$  and  $\sigma_\epsilon$  are standard deviations for the site-specific parameters.  
 203 Bao (2012) do not include slopes with respect time in their ANC observation. Eaton et al. (2014) found  
 204 that we cannot assume that the representativeness of ANC facilities is not changing.

205 Eaton and Bao (2017) report that Gaussian approximations to standard binomial models do not offer  
 206 adequate posterior predictive coverage when fit to HIV prevalence data from ANC facilities, so this work  
 207 includes the option to use one of two possible likelihoods. The first is a standard binomial model

$$Y_{r,t,1}^{s,HIV} \sim \text{Binom}(T_{r,t,1}^{s,HIV}, \rho_{r,1}^s(t)), \quad (21)$$

208 and the second is a beta-binomial model

Supplemental Table 6: Parameters used in the model of the initial state. Indexed parameters are estimated for all possible values of that index.

Param	Size	Description	Prior
$\delta_s$	$S$	Site-specific ANC bias	$N(0, \sigma_\delta)$
$\sigma_\delta$	1	ANC bias SD	$N^+(0, 1)$
$\epsilon_0$	1	Mean ANC slope	$N(0, 5)$
$\epsilon_s$	$S$	Site-specific ANC bias slope	$N(0, \sigma_\epsilon)$
$\phi_{\text{type}[s]}$	2	Type-specific ANC beta-binomial overdispersion	$N(-1, 1)$
$\sigma_\epsilon$	1	ANC bias slope SD	$N^+(0, 1)$

$$\begin{aligned} Y_{r,t,1}^{s,\text{HIV}} &\sim \text{BetaBinom}(T_{r,t,1}^{s,\text{HIV}}, \rho_{r,1}^s(t), \phi_{\text{type}[s]}) \\ \text{logit } \phi_{\text{type}[s]} &\sim N(-1, 1) \end{aligned} \quad (22)$$

209 where  $\phi_{\text{type}[s]} \in (0, 1)$  is a parameter measuring the autocorrelation between each Bernoulli trial. In the  
 210 beta-binomial case we estimate two separate values of  $\phi$ : one when  $s$  is an individual facility and one  
 211 when  $s$  is an aggregate over multiple facilities. We evaluate the effect of the choice of ANC observation in  
 212 the model specification study. This model contributes the following parameters to the model: coefficients  
 213 for the observation model,  $\delta_0$ ,  $\delta_s$ ,  $\epsilon_0$ , and  $\epsilon_s$ , and hyperparameters,  $\sigma_\delta$ ,  $\sigma_\epsilon$ , and  $\phi_{\text{type}[s]}$ , which are outlined  
 214 in Table 6.

### 215 1.4.3 ART programme data

216 The final data source used by the model is programmatic ART patient count time series. We use  $C_{r,t}$  to  
 217 denote the total number of adults receiving ART in region  $r$  at the end of time  $t$ . The compartmental  
 218 model produces estimates of the number of PLHIV living in  $r$  that are on treatment,  $A_r(t)$ , but these  
 219 estimates are not directly comparable to the corresponding  $C_{r,t}$ . While large surveys measure individuals  
 220 in their regions of residence, ART programme data record individuals where they seek treatment.  
 221 Because we fit directly to survey data and use population estimates defined by residency, we are  
 222 implicitly modelling individuals in their regions-of-residence, and therefore need to adjust  $A_r(t)$  for  
 223 treatment-seeking dynamics before it can be compared directly to  $C_{r,t}$ .

224 Following Eaton et al. (2021), we model the number of PLHIV seeking treatment in region  $r$  at time  $t$  as

$$A_r^*(t) = \sum_{\{j \sim r\}} \pi_{j \rightarrow r,t} A_j(t), \quad (23)$$

225 where  $\{j \sim r\}$  is set of regions that are adjacent to  $r$  inclusive of  $r$ ,  $\pi_{j \rightarrow r,t}$  is the time-varying probability  
 226 an individual residing in  $j$  will seek treatment in  $r$ , and  $A_j(t)$  is the number of PLHIV on ART who live  
 227 in  $j$ . Note that  $A_j(t) = \sum_{g \in \{0,1\}} A_{j,g}(t)$ .

228 We model the odds of moving from  $j$  to  $r$  relative to staying in  $r$  as

$$\begin{aligned}
\log \frac{\pi_{r \rightarrow j,t}}{\pi_{r \rightarrow r,t}} &= \log \mu_{r \rightarrow j,t} = m_j + m_0 + \beta_\pi t \\
m_j &\sim N(0, \sigma_m^2) \\
m_0 &\sim N(-3, 1) \\
\beta_\pi &\sim N(0, 5) \\
\sigma_m &\sim N^+(0, 2),
\end{aligned} \tag{24}$$

229 where  $m_j$  is a region-specific ‘‘mass’’ term,  $m_0$  is a mean mass with a prior that ensures that most people  
230 will stay in their home regions, and  $\beta_\pi$  is a time-specific slope. Following the Naomi model, we place an  
231 informative prior on  $m_0$  that assumes *a priori* that the majority of people seek treatment in their region of  
232 residence. If  $m_j$  and  $\beta_\pi$  are both fixed to be zero and region  $r$  has one neighbour, then  $m_0 = -3.0$  implies  
233 that approximately 95% of individuals residing in  $r$  will seek treatment in  $r$ .

234 We allow each  $\pi$  to vary with respect to time to account for national-level changes in ART programmes;  
235 across-the-board improvements in treatment provision could result in fewer patients needing to travel  
236 to receive adequate care and therefore, a negative value of  $\beta_\pi$ . Naomi was designed to estimate recent  
237 trends, so it covers a much shorter time period and does not need to account for long-term changes in  
238 ART programmes.

239 We use the softmax function to solve for  $\pi_{r \rightarrow j,t}$  with  $\mu_{r \rightarrow j,t} = 1.0$ :

$$\pi_{r \rightarrow j,t} = \frac{\mu_{r \rightarrow j,t}}{1 + \sum_{\{k \sim r\} \setminus r} \mu_{r \rightarrow k,t}}. \tag{25}$$

240 Then we find  $\pi_{r \rightarrow r,t} = 1 - \sum_{\{k \sim r\} \setminus r} \pi_{r \rightarrow k,t}$ .

241 These data do not have a natural denominator, so we cannot treat them as independent binomial samples.  
242 Instead, we use a negative binomial model with variance that scales both linearly and quadratically with  
243 its mean (Lindén and Mäntyniemi 2011). Let

$$\begin{aligned}
\mu &= A_r^*(t) \\
\sigma^2 &= \mu + \theta_1 \mu + \theta_2 \mu^2,
\end{aligned} \tag{26}$$

244 where  $\theta_1, \theta_2 > 0$ . We can use  $\mu$  and  $\sigma^2$  to find the typical negative binomial parameters:  $r = \mu^2 / (\sigma^2 - \mu)$   
245 and  $p = \mu / \sigma^2$ . Then we have

$$C_{r,t} \sim \text{NegBinom}(r, p). \tag{27}$$

246 For a fixed value of  $\theta_2$ , as  $\theta_1$  goes to zero, this distribution converges to a negative binomial with  
247 overdispersion  $\theta_2$ . Conversely, for a fixed value of  $\theta_1$ , as  $\theta_2$  goes to zero, it goes to a quasi-Poisson  
248 distribution. As both  $\theta_1$  and  $\theta_2$  go to zero, it returns to Poisson.

Supplemental Table 7: Parameters used in the ART patient count observation model Indexed parameters are estimated for all possible values of that index.

Param	Size	Description	Prior
$m_0$	1	Mean ART attraction mass	$N(0, 5)$
$m_r$	$R$	Regional ART attraction mass	$N(0, \sigma_m)$
$\sigma_m$	1	Regional ART attraction mass SD	$N^+(0, 1)$
$\beta_\pi$	1	ART attraction slope	$N(0, 5)$
$\omega$	1	Linear overdispersion term	$N^+(0, 2)$
$\theta$	1	Quadratic overdispersion term	$N^+(0, 2)$

249 Allowing the variance of  $C_{r,t}$  to scale both linearly and quadratically with  $\mu$  allows this model to scale  
 250 appropriately across regions of varying sizes. A one-unit change in  $\theta_2$  will result in a much larger  
 251 change in variance in a high-population region than in a low-population region, even though we do  
 252 not necessarily expect the measurement of ART patients to be quadratically higher variance in the  
 253 high-population region.

254 We set the following priors on  $\theta_1$  and  $\theta_2$ :

$$\log \theta_1, \log \theta_2 \sim N(0, 2) \quad (28)$$

255 The observation model for ART patient counts contributes the following parameters to the full set of  
 256 parameters:  $\theta_1$  and  $\theta_2$  from the quasi-negative binomial distribution, one mass,  $m_r$ , per region, a mean  
 257 mass,  $m_0$ , a time coefficient,  $\beta_t$ , and one variance  $\sigma_m^2$ , which are outlined in Table 7.

## 258 1.5 Model selection methods

259 Because incidence is not measured directly, it is not possible to directly cross-validate model results  
 260 against withheld observations of incidence, the main outcome of interest. Cross-validation simulates  
 261 how well a model generalises to new data, so we have designed a strategy focused on forecasting the  
 262 data sources we expect to continue to acquire (Vollmer et al. 2021). To that end, we evaluated the  
 263 model's performance on Malawian data using a cross-validation strategy predicts on routinely reported  
 264 indicators, represented in my model by ART programme data and facility-based ANC prevalence. We  
 265 constructed cross-validation datasets by holding out all data after one of six forecasting horizons: the first  
 266 of January in 2015, 2016, 2017, 2018, 2019, and 2020. We compared each model using out-of-sample root  
 267 mean squared error (RMSE) with respect to observed point estimates and 50%, 80%, and 95% posterior  
 268 predictive coverage separately for the two datasets (ANC facility data and ART programme data).

### 269 1.5.1 Model configurations

270 We tested every combination of choices for seven different design decisions, outlined in Table 8. First, we  
 271 allowed the likelihood for the ANC facility data to be either binomial or beta-binomial. As described  
 272 in Section 1.4.2, individual facility series shared one autocorrelation parameter and aggregate series

Supplemental Table 8: Model configuration variables tested in this chapter with descriptions of each value. Unless otherwise specified, every component refers to the transmission rate model.


Variable	Value	Description
ANC observation model	Binomial	Binomial ANC observation model
	Beta-binomial	Beta-binomial ANC observation model
ARIMA order	1	One degree of ARIMA differencing
	2	Two degrees of ARIMA differencing
	3	Three degrees of ARIMA differencing
Include slope	Yes	Exclude slope w.r.t. time
	No	Include slope w.r.t. time
Spline interval	1	Knots at one-year intervals
	5	Knots at five-year intervals
Spline order	1	Piecewise constant design matrix
	2	Piecewise linear design matrix
	3	Order-three design matrix
Transm. rate model	Constant	Constant w.r.t. time
	Linear	Linear w.r.t. time
	Latent	Include ARIMA component
Use AR	Yes	Include autoregressive term
	No	Exclude autoregressive term

273 shared another under the beta-binomial model. Second, we tested the value of including a non-linear  
274 district-level temporal component in the transmission rate model by fitting Equation (11) with intercepts  
275 only, intercepts and linear slopes with respect to time, and intercepts, slopes, and latent components.  
276 Among the models with latent components for the HIV transmission rate, we tested the effects of  
277 excluding the linear slope with respect to time, the order of the spline basis functions (one, two, or three),  
278 the distance between knots in the spline design matrices (one year or five years), the order of ARIMA  
279 differencing, and, finally, whether to include an autoregressive term. All valid combinations of these  
280 choices resulted in 146 different models, which led to 876 models to fit when combined with the six  
281 forecasting horizons. Each of these models were fit using the approximate inference strategy described  
282 by Skaug and Fournier (2006) and implemented by Kristensen et al. (2016). In the main text, we present  
283 only results from the final, selected model specification.


## 284 **2 Model selection results**

285 We summarise the results of the model specification study here and refer readers to Chapter 3 of Wolock  
286 (2022) for a detailed investigation. This study offered a few clear conclusions. First, the beta-binomial  
287 model for ANC data offered distinctly better out-of-sample fit to both the ANC data and the ART  
288 programme data than the standard binomial model (Supplemental Figure 3). Second, restricting to only  
289 models that used a beta-binomial observation model for the ANC data, none of model configuration  
290 decisions from Supplemental Table 8 resulted in superior out-of-sample fit. Instead, we were obliged to  
291 use more subjective criteria to identify a final model. Supplemental Figure 4 shows that two configurations  
292 that included a linear term with respect to time in the transmission rate model resulted in decreasing sex

293 ratios of incidence, which conflicts with widely available evidence (Risher et al. 2021). In the end, we  
 294 selected a transmission rate model with no linear term with respect to time, one degree of differencing,  
 295 an order-two spline with five-year intervals between knots, and no autoregressive term.



Supplemental Figure 3: Scatter plots of log-transformed out-of-sample RMSE for model configuration pairs that differ only in ANC observation model by dataset. The black line is equality. Points below the line of equality indicate that the beta-binomial observation model was lower and vice versa.




Supplemental Figure 4: The ratio of incidence among women to that among men from four models compared to UNAIDS. Lines correspond models without autoregressive terms, and open circles correspond to models with autoregressive terms. Black points are UNAIDS assumptions.






### 3 Fit in all districts

#### Chitipa District




Supplemental Figure 5: **Model fit to HIV data sources in Chitipa District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Karonga District




Supplemental Figure 6: **Model fit to HIV data sources in Karonga District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Likoma District




Supplemental Figure 7: **Model fit to HIV data sources in Likoma District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Mzimba District




Supplemental Figure 8: **Model fit to HIV data sources in Mzimba District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Nkhata Bay District




Supplemental Figure 9: **Model fit to HIV data sources in Nkhata Bay District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Rumphi District



Supplemental Figure 10: **Model fit to HIV data sources in Rumphi District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.


# Dedza District



Supplemental Figure 11: **Model fit to HIV data sources in Dedza District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.




# Dowa District




Supplemental Figure 12: **Model fit to HIV data sources in Dowa District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Kasungu District




Supplemental Figure 13: **Model fit to HIV data sources in Kasungu District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Lilongwe District




Supplemental Figure 14: **Model fit to HIV data sources in Lilongwe District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Mchinji District




Supplemental Figure 15: **Model fit to HIV data sources in Mchinji District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Nkhotakota District




Supplemental Figure 16: **Model fit to HIV data sources in Nkhotakota District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Ntcheu District




Supplemental Figure 17: **Model fit to HIV data sources in Ntcheu District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Ntchisi District



Supplemental Figure 18: **Model fit to HIV data sources in Ntchisi District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.


# Salima District



Supplemental Figure 19: **Model fit to HIV data sources in Salima District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.




# Balaka District




Supplemental Figure 20: **Model fit to HIV data sources in Balaka District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Blantyre District




Supplemental Figure 21: **Model fit to HIV data sources in Blantyre District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Chikwawa District




Supplemental Figure 22: **Model fit to HIV data sources in Chikwawa District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Chiradzulu District




Supplemental Figure 23: **Model fit to HIV data sources in Chiradzulu District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Machinga District




Supplemental Figure 24: **Model fit to HIV data sources in Machinga District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Mangochi District




Supplemental Figure 25: **Model fit to HIV data sources in Mangochi District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Mulanje District



Supplemental Figure 26: **Model fit to HIV data sources in Mulanje District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.


# Mwanza District



Supplemental Figure 27: **Model fit to HIV data sources in Mwanza District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.




# Neno District




Supplemental Figure 28: **Model fit to HIV data sources in Neno District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Nsanje District




Supplemental Figure 29: **Model fit to HIV data sources in Nsanje District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Phalombe District




Supplemental Figure 30: **Model fit to HIV data sources in Phalombe District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Thyolo District




Supplemental Figure 31: **Model fit to HIV data sources in Thyolo District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

# Zomba District



Supplemental Figure 32: **Model fit to HIV data sources in Zomba District, 1995-2021.** Estimated prevalence, ART coverage, untreated transmission rates, annual ART initiation probabilities, ANC prevalence, and ART patient counts in the Blantyre district in southern Malawi with household survey data (HIV prevalence and ART coverage), HIV prevalence among pregnant women attending ANC facilities, and the number of adults 15-49 receiving ART programmatic reporting data (points). Prevalence, ART coverage, incidence rate, and ART patients reflect adults aged 15-49 years. Vertical dashed lines indicate years of ART eligibility changes. Different colours on panel “ANC prevalence” indicate different ANC facilities.

## 4 Comparison to UNAIDS 2021 estimates (UNAIDS 2021)



Supplemental Figure 33: Comparison of estimated national-level annual prevalence, new infections, and ART coverage between UNAIDS 2021 estimates (point ranges) and the model presented here (green regions). Note that UNAIDS ART coverage is among all adults.

## References

- Bao, Le. 2012. "A New Infectious Disease Model for Estimating and Projecting HIV/AIDS Epidemics." *Sexually Transmitted Infections* 88 (December): i58–64. <https://doi.org/10.1136/sextrans-2012-050689>.
- Chen, Cici, Jon Wakefield, and Thomas Lumley. 2014. "The Use of Sampling Weights in Bayesian Hierarchical Models for Small Area Estimation." *Spatial and Spatio-Temporal Epidemiology* 11 (October): 33–43. <https://doi.org/10.1016/j.sste.2014.07.002>.
- Dwyer-Lindgren, Laura, Michael A. Cork, Amber Sligar, Krista M. Steuben, Kate F. Wilson, Naomi R. Provost, Benjamin K. Mayala, et al. 2019. "Mapping HIV Prevalence in Sub-Saharan Africa Between 2000 and 2017." *Nature*, May, 1. <https://doi.org/10.1038/s41586-019-1200-9>.
- Eaton, Jeffrey W., and Le Bao. 2017. "Accounting for Nonsampling Error in Estimates of HIV Epidemic Trends from Antenatal Clinic Sentinel Surveillance." *AIDS (London, England)* 31 (April): S61–68. <https://doi.org/10.1097/QAD.0000000000001419>.
- Eaton, Jeffrey W., Tim Brown, Robert Puckett, Robert Glaubius, Kennedy Mutai, Le Bao, Joshua A. Salomon, John Stover, Mary Mahy, and Timothy B. Hallett. 2019. "The Estimation and Projection Package Age-Sex Model and the r-Hybrid Model: New Tools for Estimating HIV Incidence Trends in Sub-Saharan Africa." *AIDS* 33 (December): S235. <https://doi.org/10.1097/QAD.0000000000002437>.
- Eaton, Jeffrey W., Laura Dwyer-Lindgren, Steve Gutreuter, Megan O'Driscoll, Oliver Stevens, Sumali Bajaj, Rob Ashton, et al. 2021. "Naomi: A New Modelling Tool for Estimating HIV Epidemic Indicators at the District Level in Sub-Saharan Africa." *Journal of the International AIDS Society* 24: e25788. <https://doi.org/10.1002/jia2.25788>.
- Eaton, Jeffrey W., Thomas M. Rehle, Sean Jooste, Rejoice Nkambule, Andrea A. Kim, Mary Mahy, and Timothy B. Hallett. 2014. "Recent HIV Prevalence Trends Among Pregnant Women and All Women in Sub-Saharan Africa: Implications for HIV Estimates." *AIDS (London, England)* 28 (4): S507. <https://doi.org/10.1097/QAD.0000000000000412>.
- Hastie, Trevor, and Robert Tibshirani. 1986. "Generalized Additive Models." *Statistical Science* 1 (3). <https://doi.org/10.1214/ss/1177013604>.
- Hyndman, Rob J., and George Athanasopoulos. 2018. *Forecasting: Principles and Practice*. OTexts.
- Johnson, Leigh, and Rob Dorrington. 2019. *Thembisa Version 4.2: A Model for Evaluating the Impact of HIV/AIDS in South Africa*. [https://www.thembisa.org/content/downloadPage/Thembisa4\\_2report](https://www.thembisa.org/content/downloadPage/Thembisa4_2report).
- Kassanjee, Reshma, Thomas A. McWalter, and Alex Welte. 2014. "Short Communication: Defining Optimality of a Test for Recent Infection for HIV Incidence Surveillance." *AIDS Research and Human Retroviruses* 30 (1): 45–49. <https://doi.org/10.1089/aid.2013.0113>.
- Kristensen, Kasper, Anders Nielsen, Casper W. Berg, Hans Skaug, and Brad Bell. 2016. "TMB: Automatic Differentiation and Laplace Approximation." *Journal of Statistical Software* 70 (5). <https://doi.org/10.18637/jss.v070.i05>.
- Lindén, Andreas, and Samu Mäntyniemi. 2011. "Using the Negative Binomial Distribution to Model Overdispersion in Ecological Count Data." *Ecology* 92 (7): 1414–21. <https://doi.org/10.1890/10-1831.1>.
- Risher, Kathryn A, Anne Cori, Georges Reniers, Milly Marston, Clara Calvert, Amelia Crampin,

- 337 Tawanda Dadirai, et al. 2021. "Age Patterns of HIV Incidence in Eastern and Southern Africa: A  
338 Modelling Analysis of Observational Population-Based Cohort Studies." *The Lancet HIV* 8 (7): e429–39.  
339 [https://doi.org/10.1016/S2352-3018\(21\)00069-2](https://doi.org/10.1016/S2352-3018(21)00069-2).
- 340 Skaug, Hans J., and David A. Fournier. 2006. "Automatic Approximation of the Marginal Likelihood  
341 in Non-Gaussian Hierarchical Models." *Computational Statistics & Data Analysis* 51 (2): 699–709.  
342 <https://doi.org/10.1016/j.csda.2006.03.005>.
- 343 UNAIDS. 2021. "Global HIV & AIDS Statistics — Fact Sheet." 2021. <https://www.unaids.org/en/resources/fact-sheet>.
- 344
- 345 Vollmer, Michaela A. C., Ben Glampson, Thomas Mellan, Swapnil Mishra, Luca Mercuri, Ceire Costello,  
346 Robert Klaber, Graham Cooke, Seth Flaxman, and Samir Bhatt. 2021. "A Unified Machine Learning  
347 Approach to Time Series Forecasting Applied to Demand at Emergency Departments." *BMC Emergency  
348 Medicine* 21 (1): 9. <https://doi.org/10.1186/s12873-020-00395-y>.
- 349 Wolock, Timothy M. 2022. "Bayesian Epidemic Models to Infer Spatio-Temporal HIV Incidence with  
350 Applications to Malawi." PhD thesis, London, UK: Imperial College London. [http://spiral.imperial.  
351 ac.uk/handle/10044/1/98107](http://spiral.imperial.ac.uk/handle/10044/1/98107).
- 352 Yu, Joseph Kwong-Leung, Solomon Chih-Cheng Chen, Kuo-Yang Wang, Chao-Sung Chang, Simon  
353 D. Makombe, Erik J. Schouten, and Anthony D. Harries. 2007. "True Outcomes for Patients on  
354 Antiretroviral Therapy Who Are 'Lost to Follow-up' in Malawi." *Bulletin of the World Health Organization*  
355 85 (7): 550. <https://doi.org/10.2471/BLT.06.037739>.